Welcome to our dedicated page for OCEL news (Ticker: OCEL), a resource for investors and traders seeking the latest updates and insights on OCEL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OCEL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OCEL's position in the market.
Organicell Regenerative Medicine (OTCQB: OCEL) has announced that its long COVID clinical trial is now active and enrolling patients in Miami and Los Angeles. The company has treated multiple patients for COVID under FDA programs, demonstrating promising results with its therapeutic Zofin, which may reduce inflammation and improve lung health. With over 140 million globally affected by long COVID, Organicell seeks government support to expedite the development of Zofin for broader use in treatment.
Organicell Regenerative Medicine (OTCQB:OCEL) has announced the activation of a clinical trial site at Mayo Clinic, Phoenix, for a Phase I/II study on Chronic Obstructive Pulmonary Disease (COPD). The trial will evaluate the safety and efficacy of Zofin, an intravenous infusion therapy, aimed at improving pulmonary function in COPD patients. This trial is particularly timely as COPD patients are at increased risk for severe outcomes from COVID-19. With COPD affecting around 10% of individuals over 45, the potential impact of this research is significant.
Organicell Regenerative Medicine (OTCQB:OCEL) announced the election of several new independent board members, enhancing its leadership with diverse expertise. Dr. Bhupendra Kumar Modi was appointed Chairman, bringing significant experience in healthcare and wellness. Other notable members include Chuck Bretz as Vice Chairman, and John Chistie, who has a vast financial background. The new appointments aim to improve corporate governance and strategic direction, indicating the company's focus on leveraging experience for its regenerative medicine initiatives.
Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) has appointed new key executives, including Ryan Likes as Chief Operating Officer, David Aciego as Chief Information Officer, and Jacqueline Domenech as Director of Finance.
Likes brings legal and operational expertise from Turner Broadcasting and Televisa USA. Aciego enhances technical capabilities by developing a HIPAA-compliant ERP and CRM system. Domenech adds financial oversight with over 10 years of healthcare experience. These strategic hires aim to improve company efficiency, manage risk, and support growth amid ongoing development in biological therapeutics.
Organicell Regenerative Medicine (OTCQB:OCEL) announced its entry into the skincare and haircare industries via a partnership with BeautyHealth's Hydrafacial (NASDAQ:SKIN). This collaboration aims to create an exosome booster for Hydrafacial's patented device, enhancing its efficacy by reducing inflammation and promoting collagen and elastin production. CEO Matt Sinnreich highlighted this partnership as a stepping stone towards expanding the company’s research into hair restoration and skincare applications. The partnership grants Hydrafacial exclusivity for their applications, positioning Organicell for future growth in these markets.
The Beauty Health Company (NASDAQ:SKIN) has partnered with Organicell to develop a groundbreaking exosome booster targeting aging and inflammation. This innovative product will utilize Organicell's advanced exosome technology, harnessing over 300 cytokines and growth factors. With a rapid development process, the booster is expected to enhance Hydrafacial's offerings and will launch in early 2024. This collaboration capitalizes on co-creation, allowing the company to stay ahead in the skincare market by responding quickly to consumer demands for regenerative treatments.
